PSYPAN

PsyPAN was founded in 2021 by Ian Roullier and Leonie Schneider, both participants in clinical trials using psilocybin to treat depression... PsyPAN aims to give a collective voice to all participants and help improve participant safety and wellbeing by building best practice across all levels of the global psychedelic sector. This will be achieved by providing consultancy and advocacy services to organisations and by empowering people to become part of a community that helps shape future trials and treatments... PsyPAN aims to pool the lived experiences of participants to help create more effective treatment models and maximise positive outcomes. Together participants can help shape guidelines that clinical trials and legal psychedelic treatment centres worldwide can follow where participant safety and wellbeing are put first.

Primary location: London United Kingdom